Washington, D.C. 20549

                          FORM 8-K

                       CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 1, 2005
                    PETMED EXPRESS, INC.
   (Exact name of registrant as specified in its charter)

              Commission file number 000-28827

           FLORIDA                            65-0680967
   ---------------------------               ------------
  (State or other jurisdiction              (IRS Employer
of incorporation or organization)         Identification No.)

1441 S.W. 29th Avenue, Pompano Beach, Florida       33069
---------------------------------------------      --------
  (Address of principal executive offices)        (Zip Code)

Registrant's telephone number, including area code: (954) 979-5995

                        Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

[   ] Written communications pursuant to Rule 425 under the
      Securities Act

[   ] Soliciting material pursuant to Rule 14a-12 under the
      Exchange Act

[   ] Pre-commencement communications pursuant to Rule 14d-2(b)
      under the Exchange Act

[   ] Pre-commencement communications pursuant to Rule 13e-4(c)
      under the Exchange Act

Item 1.01  Entry into a Material Definitive Agreement

Item 1.02  Termination of a Material Definitive Agreement

     On August 1, 2005, the Company and Marc Puleo, M.D. mutually
agreed  to  terminate  his Executive Employment  Agreement.   Dr.
Puleo  will no longer serve as the Company's President.  He  will
remain employed by the Company at his current salary of $150,000.
His  current position as Chairman of the Board of Directors  (and
as  a director), remains unaffected by this agreement.  Dr. Puleo
will  continue  to assist the Company with its marketing  efforts
and  media buying.  Menderes Akdag, the Company's Chief Executive
Officer will assume the role as the Company's President.
     A copy of this Executive Employment Termination Agreement is
attached  hereto as Exhibit 10.13 and is incorporated  herein  by

Item 9.01 Financial Statements and Exhibits

     (c)  Exhibits

10.13   Marc Puleo, M.D. Executive Employment Termination Agreement


     Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.

(The "Registrant")

Date: August 1, 2005

By:  /s/  Menderes Akdag
     Menderes Akdag

     Chief Executive Officer and President
     (principal executive officer)

By:  /s/  Bruce S. Rosenbloom
     Bruce S. Rosenbloom

     Chief Financial Officer
     (principal financial and accounting officer)

                        EXHIBIT INDEX

Exhibit No.                   Description

10.13     Marc Puleo, M.D. Executive Employment Termination Agreement